Nutritional supplement

Composition

One capsule contains:

• Beta glucan     - 100 mg,
• Magnesium    -  8,75 mg,
• Vitamin C         - 30 mg,
• Manganese    - 0,15 mg,
• Selenium        -   2 mcg.

Recommendations for use:

• reducing the blood bad cholesterol and sugar level,
• strengthening the immunity, organism's resistance to colds and cancerous diseases,
• increased blood pressure, cardiac insufficiency, stenocardia.

Action of active substances

Beta glucans

Beta glucans are natural polysaccharides usually found in medicinal Japanese fungi Shiitake, Maitake, Reishi, yeast, algae, and barley. The effect of beta glucans is diverse. Beta glucans are safe and effective in reducing the blood cholesterol and low density lipoprotein concentration and in stopping the progression of arteriosclerosis. Clinical researches proved that beta glucans reduce the blood cholesterol from 8 to10 percent.
Beta glucans also reduce the absorption of carbohydrates, increase tissue sensibility to insulin, improve the metabolism processes, reduce blood glucose level, improve the defensive function of immunity, strengthen the immunity, has a strong anticancerous effect, accelerate the healing of bedsores or wounds after operations or traumas, accelerate regeneration of the skin. Beta glucans in composition with cytostatics increase their efficacy and reduce the negative cytostatics effect to the immunity system. It also has a radioprotective effect and is recommended for the patients during and after radiation therapy.
Selenium, vitamin C and manganese have antioxidative properties and increase the effect of beta glucans.
Magnesium controls an increased blood pressure, regulates the heart rhythm, and participates in activity of enzymes that regulate metabolism processes.

Effectiveness proving scientific research

* On the year 1991 the medicinal school of Kochi, Japan performed a double blind, placebo controlled trial. 120 people with throat carcinoma participated. The study showed how beta glucans affect the rise of killers amount and strengthens the immunity system. After one week the number of killers was 34% and after three weeks - even 46% higher than at the beginning of the trial. Besides, the activity of killers in the group of beta glucans increased.( p < 0,05). Beta glucans increase the activity and quantity of killers and strengthens the immunity.
* On the year 1996 The Cancer Research Institute, USA, performed a double blind, placebo controlled trial with 180 women with breast cancer for finding out the effect of beta glucans to skin lesions caused by radiotherapy. One group of patients received radiation therapy and the other group - radiation therapy together with beta glucans. After 6 months women of radiation therapy and beta glucans group had 30% less skin lesions than the women of radiation therapy group. After 11 months the number of skin lesions in beta glucans group was less than 45%. Beta glucans reduce the side effects of radiotherapy.
* On the year 2000, The Cancer Research Institute, USA performed double blind trial with 300 women with breast cancer. One group of women received chemotherapy, the second group - 10 mg/kg beta glucans and the third group - chemotherapy and the same dose of beta glucans. After one year the number of long term remissions was estimated. After combination treatment the percent of long term remissions was the highest.
* On the year 2003, the university of Kairo Helwan performed double blind, randomised, placebo controlled trial with 514 people with stomach cancer. One group used cytostatics and beta glucans and the other group - only cytostatics. In the group of cytostatics and beta glucans the reduction of lymphocytes amount was stopped and did not decrease any more, the immunity of the patients strengthened. The amount of lymphocytes in cytostatics group kept decreasing and the immunity was suppressed. ( Mutat Res.2003 Nov 10 ;541(1 – 2): 45 – 53. Helwan University, Cairo, Egypt).

Dosage

1 capsule 2 to 3 times daily with or after meals.

Warning

In case of diabetes mellitus blood sugar level may decrease substantially. It is necessary to advise with doctor or pharmacist for reducing the dose of drugs or insulin before starting the treatment.

Literature:
1. Nicolosi, R et al. Plasma lipid changes after supplementation with B-glucan fiber from yeast. Amer J Clin Nutr 70, 208-12 ,1999.
2. Hunter KW, Gault RA, Berner MD.,” Preparation of microparticulate beta-glucan from Saccharomyces cerevisiae for use in immune potentiation,” Lett Appl Microbiol;35(4):267-71, 2002.
3. Vaclav Vetvicka,PhD, Kiyomi Terayama, MD, Rosemonde Mandeville, MD,PhD, Pauline Brousseau,PhD, Bill Kourikkakis,PhD, Gary Ostroff, PhD, “Pilot Study: Orally- Administered Yeast B1,3-glucan Prophylacticaly Protectc Against Anthrax Infection and Cancer in Mice,” JANA, Vol 5, No.1, Spring 2002. Hunter K, Gault R, Jordan F, “Mode of Action of B-Glucan Immunopotentiators-Research Summary Release,” Department of Microbiology, University of Nevada School of Medicine, Jan 2001.
4. Tzianabos AO, Cisneros R.I. Channing ,”Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficiency in rats infected with antibiotic-resistant bacteria”. Laboratory Brigham and Women 's Hospital, Harvard Medical School, Boston, MA, Ann NY Acad. Sci., Oct. 25, 797:285-7, 1996. Browder W., et. al.” Beneficial effect of enhanced macrophage function in the trauma patient,” Ann Surg, May,1990. Babineau TJ, et. al. “A phase II multicenter, double blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients,”Arch Surg. 1994 Nov. 1994.
5. Patchen M.L.; “Radioprotective effect of oral administration of beta-1,3-glucan,” Armed Forces Radiobiology Research Institute, Bethesda, MD Research Report, 1989.
6. Tzianabos AO, Cisnerol RL, et al; “Protection against intraabdominal sepsis by two polysaccharide immonumodulators (Beta 1,3/1,6 glucan), J Infect Dis, 178:1,200-6. 1998.
7. Babineau TJ, Marcello P, Swails W, et al. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg. 1994;220:601-609.
8. Kimura Y, Tojima H, Fukase S, Takeda K. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol Suppl. 1994;511:192-195.
9. Nakano T, Oka K, Hanba K, Morita S. Intratumoral administration of sizofilan activates Langerhans cell and T-cell infiltration in cervical cancer. Clin Immunol Immunopathol. 1996;79:79-86. Willment JA, Gordon S, Brown GD. Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem. 2001;276:43818-43823.